Cabaletta Bio, Inc. (CABA)
Automate Your Wheel Strategy on CABA
With Tiblio's Option Bot, you can configure your own wheel strategy including CABA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CABA
- Rev/Share 0.0
- Book/Share 2.4544
- PB 0.7049
- Debt/Equity 0.2369
- CurrentRatio 3.96
- ROIC -0.8905
- MktCap 87785563.0
- FreeCF/Share -1.9631
- PFCF -0.903
- PE -0.6759
- Debt/Assets 0.1744
- DivYield 0
- ROE -0.7829
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | CABA | Evercore ISI | Outperform | In-line | $15 | $6 | Dec. 20, 2024 |
| Downgrade | CABA | Wells Fargo | Overweight | Equal Weight | $12 | $6 | Dec. 19, 2024 |
| Initiation | CABA | UBS | -- | Buy | -- | $10 | Oct. 10, 2024 |
News
Cabaletta Bio Announces Pricing of Public Offering of Securities
Published: June 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten public offering consisting of (i) 39,200,000 shares of its common stock and accompanying warrants to purchase an aggregate of 39,200,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to 10,800,000 shares of its common stock …
Read More
Cabaletta Bio: Sector Headwinds And Funding Issues
Published: June 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Cabaletta Bio's CAR T-cell therapy shows durable efficacy in autoimmune diseases, with manageable side effects and promising early clinical data updates. The company plans a BLA submission for myositis in 2027, supported by FDA's RMAT designation and a focused clinical trial strategy. Financial risk is significant: current cash plus a new offering extends runway only modestly, likely insufficient to reach commercialization without further dilution.
Read More
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 11:50 a.m. ET in Boston, MA.
Read More
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS improvement; each of these patients discontinued all immunosuppressants and are off steroids as of the latest follow-up – – Safety profile continues to suggest favorable risk-benefit in the first 10 patients dosed ; 90% of patients experienced either no CRS or Grade 1 CRS (fever) and 90% of patients experienced no ICANS – – Deep B cell depletion observed in all patients after rese-cel infusion with a transitional …
Read More
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that updated clinical data on resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) will be featured in presentations at the 2025 American Association for the Advancement of Science Annual Meeting, which is being held at the Hynes Convention Center in Boston, MA from February 13-15, 2025, and the 5th International Conference on Lymphocyte Engineering, which is being held at the Holiday Inn Munich – …
Read More
About Cabaletta Bio, Inc. (CABA)
- IPO Date 2019-10-25
- Website https://www.cabalettabio.com
- Industry Biotechnology
- CEO Dr. Steven A. Nichtberger M.D.
- Employees 161